Pall Corporation, a global leader in filtration, separation and purification, has a newly named business unit within the Pall Life Sciences division. The Pall Biotech business unit has been named to reflect an important strategic direction for the company.
Critical partnerships in the industry and alignment with regulatory agencies will play a key role in improving both the integrated and stand-alone elements of the Pall Biotech total bioprocessing solutions portfolio.
“Pall Biotech does not make drugs—we enable drug manufacturers with rapid transition from pre-clinical to commercial manufacturing,” explained Martin Smith, Chief Technology Officer of Pall Corporation. “In 2018, our Pall Life Sciences division boasts the most complete solutions from drug discovery through delivery with Pall Laboratory for research and discovery, Pall Biotech enabling next-generation manufacturing processes, and Pall Medical for patient delivery.”
The Pall Biotech portfolio of standard configurable single-use, stainless steel and hybrid technologies for fed-batch and continuous processes across upstream, downstream and formulation and filling applications enables customers to accelerate time to market by selecting cost effective, robust and reliable integrated solutions. Each customer is fully supported by Pall Biotech experts at both a local and global level.